Friday's Small-Cap Winners & Losers

Caraustar Industries is dropping.
Author:
Publish date:

Perini

(PCR)

rose after it reported a surge in third-quarter revenue. The company posted quarterly income of $9.6 million, or 36 cents a share, up from $6 million, or 22 cents a share, a year ago. Revenue doubled to $773.3 million. Analysts polled by Thomson First Call were looking for earnings of 30 cents a share and revenue of $724.2 million. The company also raised its guidance. Shares were up $4.71, or 19.5%, to $28.91.

Goodrich Petroleum

(GDP) - Get Report

climbed after the oil and gas company said it increased its drilling activity in the Bethany-Longstreet Field in the Caddo and DeSoto Parishes of northwest Louisiana. Shares were higher by $3.30, or 9.3%, to $38.81.

Interline Brands

(IBI)

gained after the building-material company reported an increase in third-quarter earnings. Looking ahead, Interline affirmed its fourth-quarter earnings guidance of 33 cents to 35 cents a share. For 2006, the company is projecting earnings of 93 cents to 95 cents a share, or $1.32 to $1.34 excluding items. Shares were trading up $1.73, or 7.5%, to $24.78.

CryptoLogic

(CRYP)

advanced after the online-gaming software company beat Wall Street's third-quarter earnings expectations. For the fourth quarter, the company expects earnings of 11 cents to 15 cents a share on revenue of $19 million to $20 million. Shares were up $2.21, or 13.3%, to $18.83.

Caraustar Industries

(CSAR)

slid following a third-quarter loss and saying it would restate its second-quarter earnings. The company reported a loss of $5.1 million, or 18 cents a share, compared with earnings of $45,000 a year ago. Revenue totaled $233.3 million, up 9% from a year ago. In addition, Caraustar said it will restate second-quarter results. Shares tumbled $2.90, or 28.7%, to $7.21.

Adventrx

(ANX)

sank after the biopharmaceutical company said it received signed subscription terms from a group of accredited and institutional investors for the purchase of 14.5 million shares at $2.75 a share. Adventrx said it expects the gross proceeds of the offering to be about $40 million. Shares dropped 30 cents, or 9.8%, to $2.77.